Forbes March 27, 2024
TOPLINE
The pharmaceutical industry is hooked on weight loss drugs, but as Big Pharma’s biggest players and upstart biotechs rush to join the booming market, experts tell Forbes the dominance of Novo Nordisk and Eli Lilly is unlikely to be toppled anytime soon.
KEY FACTS
Novo’s Ozempic and Wegovy,and Lilly’s Mounjaro and Zepbound—brand names for semaglutide and tirzepatide—are undisputed leaders among the class of GLP-1 hormone-mimicking drugs used to treat diabetes and obesity and analysts told Forbes a series of critical factors means they should be able to fend off rivals with relative ease and maintain their grip on the industry for the near future.
Being the first companies to bring GLP-1 drugs to market for obesity positions...
Today's Sponsors
Today's Sponsor